- GSK's drug Blenrep gets a positive nod from the EMA's expert panel for treating multiple myeloma.
- Analysts predict a modest upside for GSK's stock price in the coming year.
- GuruFocus estimates show potential for significant stock value growth over the next year.
GSK (GSK, Financial) has taken a noteworthy step forward after the EMA's expert panel endorsed its drug Blenrep for adult patients with relapsed or refractory multiple myeloma. This approval includes its use both as a standalone treatment and in combination therapies with bortezomib and dexamethasone or pomalidomide and dexamethasone. Investors should look forward to the European Commission's verdict expected in Q3 2025.
Analyst Price Target Predictions
The consensus one-year price target from 7 analysts suggests GSK PLC (GSK, Financial) may reach an average price of $39.20, with forecasts ranging from a high of $45.00 to a low of $34.87. This target indicates a potential upside of 0.71% from the current price of $38.92. For a deeper dive into these estimates, visit the GSK PLC (GSK) Forecast page.
Brokerage Recommendations
Analysis from 9 brokerage firms currently rates GSK PLC (GSK, Financial) at an average of 2.8, which aligns with a "Hold" status. The recommendation scale spans from 1, representing a Strong Buy, to 5, indicating a Sell.
GuruFocus Valuation Insights
According to GuruFocus' proprietary GF Value metric, GSK PLC (GSK, Financial) is projected to reach a value of $45.42 over the next year. This estimate suggests a noteworthy potential upside of 16.7% from the current trading price of $38.92. The GF Value is a comprehensive measure formulated based on historical stock price multiples, past business growth rates, and future business performance projections. More comprehensive data is accessible on the GSK PLC (GSK) Summary page.
